Actively Recruiting

Age: 12Years - 65Years
All Genders
NCT06435000

An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene

Led by Splice Bio · Updated on 2025-09-19

75

Participants Needed

20

Research Sites

148 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is an Observational Study to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene This is a multicenter study which will enroll approximately 75 subjects

CONDITIONS

Official Title

An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene

Who Can Participate

Age: 12Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Provide written consent
  • Male or female aged 12 to 65 years old
  • Diagnosis of STGD1 caused by bi-allelic likely pathogenic or pathogenic variants in the ABCA4 gene confirmed by a certified laboratory
  • History of STGD1 progression within the last 2 years as judged by the investigator
  • Eligible eyes must have best corrected visual acuity between 24 and 88 ETDRS letters (20/20 to 20/320 Snellen equivalent)
  • Clinical signs of macular lesions consistent with Stargardt Disease
  • Fundus autofluorescence measurement showing definitely decreased autofluorescence as confirmed by the Central Reading Center
  • Total lesion fully imaged with lesion borders at least 300 microns from image edges
  • Eligible eyes must have clear ocular media and allow good quality retinal imaging with pupil dilation
Not Eligible

You will not qualify if you...

  • Immediate family members of the Sponsor or study site personnel
  • Any other eye disease affecting study procedures or outcomes (e.g., cataracts; enrollment allowed 90 days after cataract surgery)
  • Presence of other likely pathogenic variants in retinal dystrophy genes not related to STGD1
  • Intraocular surgery or thermal laser treatment within 90 days before study entry, or prior thermal laser in the macular region
  • Major surgery within 30 days before screening or planned during the study
  • Unwillingness to stop vitamin A, beta-carotene, liver-based supplements, or prescription oral retinoids during the study
  • Participation in investigational therapy within 90 days or 5 half-lives prior to screening; any history of gene therapy, stem cell therapy, retinal chip implantation, or eye injections
  • Known serious allergies to fluorescein dye, eye drops used for dilation or anesthesia, or history of anaphylaxis
  • History of amblyopia in eligible eyes
  • Any significant medical condition or abnormal lab test that may increase risk or affect study participation or results, as judged by the investigator and Medical Monitor

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 20 locations

1

Shiley Eye Institute

San Diego, California, United States, 92093

Actively Recruiting

2

UCHealth Sue Anschutz-Rodgers Eye Center

Aurora, Colorado, United States, 80045

Actively Recruiting

3

Vitreo Retinal Associates

Gainesville, Florida, United States, 32607

Actively Recruiting

4

Bascom Palmer Eye Institute

Miami, Florida, United States, 33136

Actively Recruiting

5

Emory University

Atlanta, Georgia, United States, 30322

Actively Recruiting

6

Wilmer Eye Institute, Johns Hopkins University MD 21287

Baltimore, Maryland, United States, 21287

Actively Recruiting

7

Massachusetts Eye and Ear Infirmary

Boston, Massachusetts, United States, 02114

Actively Recruiting

8

Kellogg Clinical Research Center

Ann Arbor, Michigan, United States, 48105

Actively Recruiting

9

Columbia University Medical Center

New York, New York, United States, 10032

Actively Recruiting

10

CUIMC/Edward S. Harkness Eye Institute

New York, New York, United States, 10032

Actively Recruiting

11

Duke Eye Center

Durham, North Carolina, United States, 27710

Actively Recruiting

12

Oregon Health & Science University

Portland, Oregon, United States, 97239

Actively Recruiting

13

Retina Foundation of the Southwest

Dallas, Texas, United States, 75231

Actively Recruiting

14

University of Wisconsin, Madison

Madison, Wisconsin, United States, 53715

Actively Recruiting

15

Universitätsklinikum Bonn, Klinik für Augenheilkunde

Bonn, Germany, 53127

Actively Recruiting

16

University Eye Hospital Tübingen

Tübingen, Germany, 72076

Actively Recruiting

17

Moorfields Eye Hospital

London, London, United Kingdom, EC1V 2PD

Actively Recruiting

18

Leeds Teaching Hospitals NHS Trust

Leeds, United Kingdom, LS9 7T

Actively Recruiting

19

University of Manchester - The Old St Mary's Hospital

Manchester, United Kingdom, M13 9WL

Actively Recruiting

20

Oxford Eye Hospital

Oxford, United Kingdom, OX3 9DU

Actively Recruiting

Loading map...

Research Team

S

SpliceBio

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here